Author:
Meinag Fatemeh Ebadi,Fatahi Mina,Vahedian Vahid,Maroufi Nazila Fathi,Mosayyebi Bashir,Ahmadi Elham,Rahmati Mohammad
Publisher
Springer Science and Business Media LLC
Reference174 articles.
1. Abd EL Fattah YK, Abulsoud AI, Abdelhamid SG, Abdelhalim S, Hamdy NM (2023) CCDC144NL-AS1/hsa-miR-143-3p/HMGA2 interaction: In-silico and clinically implicated in CRC progression, correlated to tumor stage and size in case-controlled study; step toward ncRNA precision. Intl J Biol Macromol 253:126739
2. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB (2005) The liposomal formulation of doxorubicin. Methods in enzymology. Elsevier
3. Akbari Kordkheyli V, Rashidi M, Shokri Y, Fallahpour S, Variji A, Bazi A, Nabipour Ghara E, Hosseini SM (2021) CRISPER/CAS system, a novel tool of targeted therapy of drug-resistant lung cancer. Adv Pharmaceut Bull 12:262–273
4. Al-Malky HS, Al Harthi SE, Osman A-MM (2020) Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Prac 26:434–444
5. Alizadeh MN, Rashidi M, Muhammadnejad A, Zanjani TM, Ziai SA (2018) Antitumor effects of umbelliprenin in a mouse model of colorectal cancer. Iranian J Pharmaceut Res: IJPR 17:976